Study evaluating intranasal anti-CD3 for treatment of Alzheimer’s disease published in the PNAS journal

Tiziana Life Sciences Ltd. (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”, in the preeminent journal, Proceedings of the National Academy of Sciences (PNAS), that supports foralumab’s mechanism as a potential treatment for Alzheimer’s disease (AD), a difficult-to-treat neuroinflammatory disease.

Tandem reports 224 injuries related to faulty insulin pump app

Dive Brief: Tandem Diabetes Care is recalling a version of its t:connect app for iPhone because of a fault that could drain insulin pump batteries,

May 9, 2024

Study traces the natural evolution of earliest stages of human cancers

Cancer cells-to-be accumulate a series of specific genetic changes in a predictable and sequential way years before they are identifiable as pre-malignancies, researchers at Stanford

July 8, 2023

Hyperoxia Improves Some Respiratory Outcomes Post-Anesthesia in Small Study

HOUSTON — A liberal oxygen intervention to induce hyperoxia improved respiratory disturbances in post-operative patients during recovery from anesthesia, results from a small single-blind trial

June 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.